Lantern Pharma's LP-284 Granted FDA Orphan Drug Designation for High-Grade B-cell Lymphoma Treatment

Lantern Pharma Inc., an AI-driven company pioneering targeted cancer therapies through its RADR® AI and ML platform, has received FDA Orphan Drug Designation (ODD) for LP-284 in treating high-grade B-cell lymphoma with MYC and BCL2 rearrangements. LP-284, a novel small molecule agent, induces DNA damage in cancer cells, leading to their demise. Lantern is actively developing LP-284 for aggressive B-cell NHL, demonstrating potent anti-tumor activity in preclinical models. The swift progression of LP-284 from RADR® A.I. insights to clinical trials within approximately 2.5 years underscores Lantern's commitment to advancing transformative cancer treatments.